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Although the incidence of gastric cancer has declined in recent years, it is still the fourth most common cancer in the world and the second leading cause of cancer‐related deaths worldwide.[1](#cas13158-bib-0001){ref-type="ref"} More than 950 000 new cases occur each year. An estimated 720 000 patients died from gastric cancer in 2012. More than 70% of cases occur in developing countries.[2](#cas13158-bib-0002){ref-type="ref"} Patients with advanced stage gastric cancer have an extremely poor survival rates.[3](#cas13158-bib-0003){ref-type="ref"}

To date, diagnosis of gastric cancer has been based on clinical symptoms together with techniques such as endoscopy and barium meal test; however, these methods have certain drawbacks in the detection of gastric cancer. In addition, serum tumor markers, such as CEA, CA19‐9, and CA72‐4 also have limited sensitivity and specificity for gastric cancer screening.[4](#cas13158-bib-0004){ref-type="ref"} Furthermore, because of the lack of expression of these markers in the early stages of cancer, their serum levels are not sufficiently high for early detection. Therefore, there is a need for novel, reliable, non‐invasive biomarkers of gastric cancer.

The immune system recognizes tumor cells even in early stages of cancer,[5](#cas13158-bib-0005){ref-type="ref"}, [6](#cas13158-bib-0006){ref-type="ref"} including a mutated version of the p53 tumor suppressor protein that is overexpressed in gastric cancer.[7](#cas13158-bib-0007){ref-type="ref"} Although serum p53 antibodies have been detected even in the early stages of tumors, the positive rate for stage I tumors is \<10%.[8](#cas13158-bib-0008){ref-type="ref"}, [9](#cas13158-bib-0009){ref-type="ref"}, [10](#cas13158-bib-0010){ref-type="ref"} To overcome this problem, subsequent studies have provided better sensitivity in the diagnosis of cancer by screening for multiple autoantibodies against a panel of TAAs.[11](#cas13158-bib-0011){ref-type="ref"}, [12](#cas13158-bib-0012){ref-type="ref"}, [13](#cas13158-bib-0013){ref-type="ref"}, [14](#cas13158-bib-0014){ref-type="ref"}, [15](#cas13158-bib-0015){ref-type="ref"}, [16](#cas13158-bib-0016){ref-type="ref"}, [17](#cas13158-bib-0017){ref-type="ref"}, [18](#cas13158-bib-0018){ref-type="ref"}, [19](#cas13158-bib-0019){ref-type="ref"}, [20](#cas13158-bib-0020){ref-type="ref"}

The panel of six antigens selected in this study includes a well‐recognized TAA, p53, which is mutated in a large number of cancers. This antigen was the first described to elicit autoantibodies in cancer.[21](#cas13158-bib-0021){ref-type="ref"} Such anti‐p53 antibodies can, in some cases, be detected before the detection of cancer using other methods.[22](#cas13158-bib-0022){ref-type="ref"}, [23](#cas13158-bib-0023){ref-type="ref"} Heat shock protein 70 is possibly the most intriguing because it is a stress response protein involved in various cell processes, such as folding and assembly of newly synthesized proteins as well as inhibition of apoptosis through the caspase‐dependent pathway.[24](#cas13158-bib-0024){ref-type="ref"} Overexpression of HSP70 leads to increased resistance to apoptosis‐inducing agents, such as tumor necrosis factor‐α and doxorubicin,[25](#cas13158-bib-0025){ref-type="ref"} and can promote the growth and metastatic potential of tumors in rodent models.[26](#cas13158-bib-0026){ref-type="ref"} Moreover, autoantibodies against HSP70 have been identified in esophageal squamous cell carcinoma.[27](#cas13158-bib-0027){ref-type="ref"} Both purified HCC‐22‐5 and HCC‐22‐5 fusion proteins have an immune response to serum antibodies of HCC. Anti‐HCC‐22‐5 antibody is not found in sera of patients with gastroenterological disease or lung cancer or in sera of healthy individuals, but it is found in sera of patients with HCC as well as those with other liver diseases.[28](#cas13158-bib-0028){ref-type="ref"} Peroxiredoxin (Prx) VI is a member of the *Prx* gene family.[29](#cas13158-bib-0029){ref-type="ref"} Peroxiredoxins are ubiquitous enzymes, such as antioxidant enzymes, that control intracellular levels of H~2~O~2~ by catalyzing its reduction to water. These proteins are stress inducible and associated with cell‐signaling pathways. They also participate in cellular antioxidant defense by inducing cell proliferation and protecting cells from undergoing apoptosis.[30](#cas13158-bib-0030){ref-type="ref"} KM‐HN‐1 was identified in the serum of a patient with squamous cell carcinoma of the head and neck by means of serologic identification of antigens by recombinant expression cloning and a testis cDNA expression library. The aberrant expression of the *KM‐HN‐1* gene in a broad spectrum of human neoplasms characterizes KM‐HN‐1 as a cancer antigen.[31](#cas13158-bib-0031){ref-type="ref"} A cancerous inhibitor of protein phosphatase 2A, p90, was cloned using a cDNA expression library with autoantibodies from patients with HCC.[32](#cas13158-bib-0032){ref-type="ref"} It has been reported as an endogenous inhibitor of the phosphatase activity of protein phosphatase 2A, which extends the half‐life of oncogenic protein c‐Myc and promotes cell survival by regulating protein kinase B dephosphorylation.[33](#cas13158-bib-0033){ref-type="ref"}

Here we provide a novel hypothesis regarding the efficiency of a panel consisting of six antigens to help discriminate gastric cancer patients from controls. Using an optimal combination of the six markers determined above, we assayed 173 samples that included 73 control samples and validated the outcome with 248 independent samples.

Materials and Methods {#cas13158-sec-0002}
=====================

Ethical approval {#cas13158-sec-0003}
----------------

Informed patient consent was obtained, and the study was approved by the Ethics Committee of Chiba Cancer Center (no. 21‐26; Chiba, Japan) and Toho University School of Medicine (nos. 22‐112 and 22‐047; Tokyo, Japan).

Collection of serum samples {#cas13158-sec-0004}
---------------------------

Serum samples were obtained from BioBank (Tokyo, Japan), and collected at the Department of Gastroenterological Surgery, Chiba Cancer Center, according to established standard procedures and stored at −80°C until use.

Gastric cancer was defined on the basis of gastroscopy and was confirmed with histopathology. Tumor stage was clinically determined with gastroscopy and computed tomography and was defined according to the seventh edition of the American Joint Committee on Cancer Staging Manual.[34](#cas13158-bib-0034){ref-type="ref"} Healthy controls in the test cohort were without any previous malignant disease.

The cohorts analyzed for this retrospective study were characterized as follows. Autoantibody test cohort: (i) 100 patients with gastric cancer, whose serum samples were obtained from BioBank Japan; and (ii) 79 healthy controls. Autoantibody validation cohort: (i) 248 patients with gastric cancer, whose serum samples were collected at Chiba Cancer Center; and (ii) 74 healthy controls.

Purification of **recombinant TAAs** {#cas13158-sec-0005}
------------------------------------

For the expression and purification of recombinant protein, full‐length cDNA of the TAAs p53 (GenBank accession number: [AB082923](AB082923)), HCC‐22‐5 ([NM 004683](NM004683)), HSP70 (NM 004134), PrxVI (NM 004905), KM‐HN‐1 ([NM152775](NM152775)), and p90 ([AF334474](AF334474)) were amplified by polymerase chain reaction. The amplified gene was inserted into a plasmid expressed as tag. These recombinant proteins were expressed in *Escherichia coli* BL21‐CodonPlus (DE3)‐RIL (Stratagene, La Jolla, CA, USA) and were dissolved in PBS. The TAA extract was applied to Ni Sepharose 6 Fast Flow (GE Healthcare, Little Chalfont, UK), and the column was washed with 50 mM imidazole in PBS. Purified TAA recombinant proteins were eluted with 200 mM imidazole in PBS. The expression and purity of the recombinant proteins were examined with 12.5% SDS‐PAGE. DNA sequencing analysis confirmed that the correct gene was inserted into the constructed plasmid.

Detection of serum antibodies and other conventional tumor markers {#cas13158-sec-0006}
------------------------------------------------------------------

Serum samples from patients and healthy controls were analyzed by ELISA, as previously described.[6](#cas13158-bib-0006){ref-type="ref"} Briefly, purified recombinant proteins were coated onto 96‐well microtiter plates (Maxisorp; Nunc, Rochester, NY, USA). Tumor‐associated antigens were diluted in PBS to final concentrations of 0.5--5.0 μg/mL and added to the plates (100 μL/well), which were then incubated overnight at 4°C; PBS was used as control. After two washes with PBS, the proteins were blocked with 200 μL PBS containing 1% BSA and 5% sucrose at room temperature for 3 h. All human serum samples were diluted (1:100) in PBS containing 0.15% Tween 20, 1% casein, and 0.2 mg/mL *E. coli* extract. Then, 100 μL diluted serum was added to each TAA‐ or PBS‐coated well and incubated at room temperature at 20 g for 60 min. After washing with PBS containing 0.05% Tween‐20 (PBST) four times, 100 μL HRP‐conjugated antihuman IgG (1:5000; MBL, Nagoya, Japan) diluted in 20 mM HEPES, 135 mM NaCl, 1% BSA, and 0.1% hydroxyphenylacetic acid was added to each well as a secondary antibody and incubated at room temperature at 20 g for 60 min. The wells were washed four times with PBST buffer, and autoantibodies were detected by addition of 100 μL 3,3′,5,5′‐tetramethylbenzidine substrate. After incubation at room temperature for 30 min, the reaction was stopped by the addition of 0.25 N sulfuric acid (100 μL/well). Absorbance was measured at 450 nm using a SUNRISE Microplate Reader (Tecan Japan Co., Ltd, Kawasaki, Japan). The TAA signals were evaluated by calculating the difference in absorbance between the wells containing TAAs and those containing PBS. Serum CEA and CA19‐9 were also evaluated as previously described.[35](#cas13158-bib-0035){ref-type="ref"}

Assay cut‐off values {#cas13158-sec-0007}
--------------------

The cut‐off value designating positive reactivity was defined as an optical density value greater than the mean + 3× SD of the normal controls from the test cohort.[12](#cas13158-bib-0012){ref-type="ref"}, [17](#cas13158-bib-0017){ref-type="ref"} The specificity of the assay was calculated as the percentage of the healthy controls from whom a negative result was obtained.

Statistical analyses {#cas13158-sec-0008}
--------------------

All analyses were carried out using [spss]{.smallcaps} version 17.0 (SPSS, Chicago, IL, USA), Microsoft Excel (Microsoft, Redmond, WA, USA), or GraphPad Prism software (GraphPad, La Jolla, CA, USA). The number and proportion of positive samples were presented with 95% exact confidence intervals (CIs) for binomial proportions. The false positive rate, false negative rate, positive predictive value, negative predictive value, positive likelihood ratio, and negative likelihood ratio, all with 95% CIs, were presented to improve clinical interpretation. The χ^2^‐test or Fisher\'s exact test was used to determine when the proportion of positive results was significantly different between patients with cancer and healthy controls, and to identify correlations of individual and combined antibody assay positivity with clinical parameters. The correlation between overall survival and autoantibody status was calculated using the log--rank test, and the results are presented as curves determined using the Kaplan--Meier method. In all tests, we considered *P*‐values of \<0.05 (two‐sided) to indicate statistical significance.

Results {#cas13158-sec-0009}
=======

Autoantibodies in gastric cancer {#cas13158-sec-0010}
--------------------------------

In total, 421 participants were recruited, 179 in the test cohort and 322 in the validation cohort. The presence of autoantibodies to all TAAs in both cohorts is shown for one concentration of antigen in the scatter plots in Figure [1](#cas13158-fig-0001){ref-type="fig"}. All six TAAs were clearly elevated in serum samples from patients with gastric cancer compared with serum from healthy controls. The levels of autoantibodies to individual antigens in patients with gastric cancer and healthy controls are shown in Table [1](#cas13158-tbl-0001){ref-type="table-wrap"} and Figure [2](#cas13158-fig-0002){ref-type="fig"}. The levels of autoantibodies to all of these antigens were significantly different in these two groups. The cut‐off value for a positive response to an antigen was defined as the mean + 3× SD of the healthy controls. In the validation cohort, levels of autoantibodies to all antigens were significantly different between patients with gastric cancer and healthy controls. Using all six antibodies provided an enhanced panel sensitivity of 49.0% (95% CI, 39.2--58.8%) and 52.0% (95% CI, 42.2--61.8%) in the test and validation cohorts, respectively. The importance of autoantibody responses to individual antigens in the panel assay varied. Results in the validation cohort using the cut‐off values for individual autoantibodies of the test cohort were similar to the results in the test cohort (Table [2](#cas13158-tbl-0002){ref-type="table-wrap"}).

![Enzyme‐linked immunosorbent assay antibody titers of individual patients and normal controls for tumor‐associated antigens (TAAs). Scatter plots of optical density (OD) values of autoantibodies (a) in serum from patients with gastric cancer (C) (*n* = 100) and from healthy controls (N) (*n* = 79) in the test cohort and (b) in serum from patients with gastric cancer (*n* = 248) and from healthy controls (*n* = 74) in the validation cohort. HSP70, heat shock protein 70; p90; p90 TAA (CYP2A); PrxVI, peroxiredoxin VI.](CAS-108-308-g001){#cas13158-fig-0001}

###### 

Frequency of autoantibodies to tumor‐associated antigens (TAAs) in test and validation cohorts of gastric cancer patients and normal controls

  Group               p53                  Hsp70                HCC‐22‐5             Prx6                 KM‐HN‐1              p90                  Panel
  ------------------- -------------------- -------------------- -------------------- -------------------- -------------------- -------------------- -------------------
  Test cohort                                                                                                                                       
  Sensitivity         15.0 (8.0--22.0)     11.0 (4.87--17.1)    7.0 (2.0--12.0)      10.0 (4.1--15.9)     6.0 (1.3--10.7)      8.0 (2.7--13.3)      49.0 (39.2--58.8)
  Specificity         97.5 (94.4--100.0)   98.7 (96.5--100.0)   98.7 (96.5--100.0)   98.7 (96.5--100.0)   98.7 (96.5--100.0)   98.7 (96.5--100.0)   92.4 (87.2--97.6)
  Validation cohort                                                                                                                                 
  Sensitivity         16.5 (9.3--23.8)     25.0 (16.5--33.5)    8.9 (3.3--14.4)      7.7 (2.4--12.9)      6.0 (1.7--10.7)      11.3 (5.1--17.5)     52.0 (42.2--61.8)
  Specificity         97.3 (94.1--100.0)   97.3 (94.4--100.0)   97.3 (94.4--100.0)   97.3 (94.4--100.0)   94.6 (90.2--99.0)    95.9 (92.1--99.8)    90.5 (84.8--96.3)

All values are given in percentage positivity with 95% confidence interval in each group. Hsp70, heat shock protein 70; p90, p90 tumor‐associated antigen (CYP2A); Panel, autoantibody positivity to any one of the six antigens; PrxVI, peroxiredoxin VI.

John Wiley & Sons, Ltd

![Sensitivity of tumor‐associated antigens and panel of six autoantibodies for detecting gastric cancer. Bar graphs show the sensitivity of each antigen or panel. HSP70, heat shock protein 70; p90, p90 tumor‐associated antigen (CYP2A); PrxVI, peroxiredoxin VI.](CAS-108-308-g002){#cas13158-fig-0002}

###### 

Results of the autoantibody panel in the diagnosis of gastric cancer

  Group               Sensitivity         Specificity         FPR               FNR               PPV                 NPV                 PLR                  NLR
  ------------------- ------------------- ------------------- ----------------- ----------------- ------------------- ------------------- -------------------- -------------------
  Test cohort         49.0 (39.2--58.8)   92.4 (87.2--97.6)   7.6 (2.4--12.8)   51 (41.2--60.8)   89.1 (83.0--95.2)   58.9 (49.2--68.5)   6.45 (1.64--11.27)   0.55 (0.00--2.00)
  Validation cohort   52.0 (42.2--61.8)   90.5 (84.8--96.3)   9.5 (3.7--15.2)   48 (38.2--57.8)   94.9 (90.5--99.2)   36 (26.6--45.4)     5.5 (1.03--9.97)     0.53 (0.00--1.95)

All values are given with 95% exact confidence interval in each group. FNR, false negative rate; FPR, false positive rate; NLR, negative likelihood ratio; NPV, negative predictive value; Panel, autoanitibody positivity to any one of the six antigens; PLR, positive likelihood ratio; PPV, positive predictive value.

John Wiley & Sons, Ltd

Clinicopathological features and autoantibody status in patients with gastric cancer {#cas13158-sec-0011}
------------------------------------------------------------------------------------

Patient samples in the validation cohort were obtained at Chiba Cancer Center. The demographics of the patients and the clinicopathological characteristics of their tumors are shown in Table [3](#cas13158-tbl-0003){ref-type="table-wrap"}. Significantly more male than female patients were autoantibody panel positive (*P* = 0.025). No other patient characteristics were significantly related to autoantibody panel status (Table [4](#cas13158-tbl-0004){ref-type="table-wrap"}). In 28.7% of the autoantibody‐positive individuals in panel 1 of 6, autoantibodies were raised to a second antigen in samples from patients with gastric cancer in the validation cohort. We assessed the correlations between clinicopathological features and the positive number of antigens (Table [5](#cas13158-tbl-0005){ref-type="table-wrap"}). None of the features were found to be significantly related to the positive number of autoantibodies (1 or ≥2).

###### 

Patient details and clinicopathological features in validation cohort

  ----------------------------------- -------------
  Number                              248
  Gender, *n* (%)                     
  Male                                181 (73.0)
  Female                              67 (23.0)
  Mean age ± SD, years                67.1 ± 10.5
  Age range, years                    36--89
  Depth of tumor invasion, *n* (%)    
  T1                                  137 (55.2)
  T2                                  32 (12.9)
  T3                                  31 (12.5)
  T4                                  48 (19.4)
  Lymph node metastasis, *n* (%)      
  Positive                            87 (35.1)
  Negative                            125 (50.4)
  Unknown                             36 (14.5)
  Distant metastasis, *n* (%)         
  Positive                            21 (16.5)
  Negative                            227 (83.5)
  Unknown                             0 (0.0)
  Peritoneal dissemination, *n* (%)   
  Positive                            31 (12.5)
  Negative                            217 (87.5)
  Unknown                             0 (0.0)
  TNM stage, *n* (%)                  
  I                                   155 (62.5)
  II                                  8 (3.2)
  III                                 28 (11.3)
  IV                                  57 (23.0)
  Unknown                             0 (0.0)
  ----------------------------------- -------------

John Wiley & Sons, Ltd

###### 

Patient details of panel positive in validation cohort

  Positive                            −             \+           *P*
  ----------------------------------- ------------- ------------ -------
  Number (%)                          119 (48.0)    129 (52.0)   
  Gender, *n* (%)                                                
  Male                                79 (43.6)     102 (56.4)   0.025
  Female                              40 (59.7)     27 (40.3)    
  Mean age ± SD, years                66.3 ± 10.9   68.5 ± 9.3   
  Age range, years                    38--89        37--87       
  Depth of tumor invasion, *n* (%)                               
  T1                                  63 (25.4)     74 (29.8)    0.421
  T2                                  16 (6.5)      16 (6.5)     
  T3                                  19 (7.7)      12 (4.8)     
  T4                                  21 (8.5)      27 (10.9)    
  Lymph node metastasis, *n* (%)                                 
  Positive                            40 (16.1)     39 (15.7)    0.730
  Negative                            60 (24.2)     65 (26.2)    
  Unknown                             19 (7.7)      25 (10.1)    
  Distant metastasis, *n* (%)                                    
  Positive                            20 (8.0)      21 (8.5)     0.705
  Negative                            99 (40.0)     108 (43.5)   
  Unknown                             0 (0.0)       0 (0.0)      
  Peritoneal dissemination, *n* (%)                              
  Positive                            16 (6.5)      15 (6.0)     0.972
  Negative                            103 (41.5)    114 (46.0)   
  Unknown                             0 (0.0)       0 (0.0)      
  TNM stage, *n* (%)                                             
  I                                   70 (28.2)     85 (34.3)    0.727
  II                                  7 (2.8)       1 (0.4)      
  III                                 14 (5.6)      14 (5.6)     
  IV                                  28 (11.3)     29 (11.7)    
  Unknown                             0 (0.0)       0 (0.0)      
  CEA, *n* (%)                                                   
  Positive                            17 (6.85)     28 (11.3)    0.130
  Negative                            102 (41.1)    101 (40.7)   
  CA19‐9, *n* (%)                                                
  Positive                            15 (6.04)     20 (8.06)    0.512
  Negative                            104 (41.9)    109 (44.0)   

CA, carbohydrate antigen; CEA, carcinoembryonic antigen.

John Wiley & Sons, Ltd

###### 

Gastric cancer patients positive for one or multiple autoantibodies in validation cohort

  Number of antigen positive          1            ≥2            *P*
  ----------------------------------- ------------ ------------- -------
  Number (%)                          92 (71.3)    37 (28.7)     
  Gender, *n* (%)                                                
  Male                                69 (53.5)    33 (25.6)     0.073
  Female                              23 (17.8)    4 (3.1)       
  Mean age ± SD, years                68.5 ± 9.3   66.7 ± 13.5   
  Age range, years                    37--87       36--85        
  Depth of tumor invasion, *n* (%)                               
  T1                                  51 (39.5)    23 (17.8)     0.310
  T2                                  15 (11.6)    1 (0.8)       
  T3                                  9 (7.0)      3 (2.3)       
  T4                                  17 (13.2)    10 (7.8)      
  Lymph node metastasis, *n* (%)                                 
  Positive                            28 (21.7)    11 (8.5)      0.796
  Negative                            48 (37.2)    17 (13.2)     
  Unknown                             16 (12.4)    9 (7.0)       
  Distant metastasis, *n* (%)                                    
  Positive                            14 (10.9)    7 (5.4)       0.969
  Negative                            78 (60.5)    30 (23.3)     
  Unknown                             0 (0.0)      0 (0.0)       
  Peritoneal dissemination, *n* (%)                              
  Positive                            8 (6.2)      7 (5.4)       0.410
  Negative                            84 (65.1)    30 (23.3)     
  Unknown                             0 (0.0)      0 (0.0)       
  TNM stage, *n* (%)                                             
  I                                   62 (48.1)    23 (17.8)     0.759
  II                                  0 (0.0)      1 (0.8)       
  III                                 12 (9.3)     2 (1.6)       
  IV                                  18 (14.0)    11 (8.5)      
  Unknown                             0 (0.0)      0 (0.0)       
  CEA, *n* (%)                                                   
  Positive                            19 (14.7)    9 (7.0)       0.825
  Negative                            73 (56.6)    28 (21.7)     
  CA19‐9, *n* (%)                                                
  Positive                            16 (12.4)    4 (3.10)      0.513
  Negative                            76 (58.9)    33 (25.6)     

CA, carbohydrate antigen; CEA, carcinoembryonic antigen.

John Wiley & Sons, Ltd

Autoantibody panel for early detection {#cas13158-sec-0012}
--------------------------------------

To verify the diagnostic power of this six‐autoantibody panel, we further assessed its sensitivity for the detection of gastric cancer. We first compared its sensitivity with the sensitivities of the traditional tumor markers CEA and CA19‐9. In the validation cohort, the sensitivities of CEA and CA19‐9 were 18.1% and 14.1%, respectively, whereas the sensitivity of the six‐autoantibody panel was 52.0%, and there was a significant difference between the sensitivities of the panel and traditional tumor markers (Fig. [3](#cas13158-fig-0003){ref-type="fig"}). The sensitivity of the panel was significantly higher than that of combinations, including CEA and CA19‐9. Furthermore, the sensitivity of the six‐autoantibody panel plus CEA and CA19‐9 was significantly higher than that of the six‐autoantibody panel alone.

![Sensitivity of autoantibody panel with traditional tumor markers carcinoembryonic antigen (CEA) and carbohydrate antigen 19‐9 (CA19‐9) for detecting gastric cancer.](CAS-108-308-g003){#cas13158-fig-0003}

To assess the usefulness of the panel in the clinical setting, we examined the sensitivity of the panel for detecting gastric cancers with various clinical features. We found that the sensitivity of the panel did not differ between tumors that differed in any of the features that we assessed in this study: depth of tumor invasion (T1 or ≥T2), lymph node metastasis (+ or −), distant metastasis (+ or −), peritoneal dissemination (+ or −), TNM stage (I or ≥II), or pathological type (such as tubular adenocarcinoma, signet ring cell carcinoma, and papillary adenocarcinoma). In contrast, with conventional tumor markers, even with the combination of CEA and CA19‐9, the sensitivity of the marker for detecting gastric cancers significantly differed in tumors with different clinical features. In brief, conventional tumor markers could not detect gastric cancer in the early stages (Fig. [4](#cas13158-fig-0004){ref-type="fig"}).

![Sensitivity for tumors with various clinical features in patients with gastric cancer. (a) Depth of tumor invasion. (b) Lymph node metastasis. (c) Distant metastasis. (d) Peritoneal dissemination. (e) TNM stage. (f) Pathological type. \**P *\< 0.05; \*\**P* \< 0.001. CA19‐9, carbohydrate antigen 19‐9; CEA, carcinoembryonic antigen.](CAS-108-308-g004){#cas13158-fig-0004}

Prognostic role of autoantibodies in patients with gastric cancer {#cas13158-sec-0013}
-----------------------------------------------------------------

We evaluated the 3‐year survival rates of the autoantibody‐positive and ‐negative groups and found no differences between them (Fig. [5](#cas13158-fig-0005){ref-type="fig"}a).

![Overall survival curves of gastric cancer patients with different autoantibody status. (a) Autoantibody‐positive and ‐negative groups. (b) Group with ≥2 positive autoantibodies and group with one autoantibody positive or negative.](CAS-108-308-g005){#cas13158-fig-0005}

We also divided the patients into two groups; the group with patients positive for two or more autoantibodies had a worse prognosis than that of the other group with patients positive for no or one antibody (Fig. [5](#cas13158-fig-0005){ref-type="fig"}b).

Discussion {#cas13158-sec-0014}
==========

Diagnosis of gastric cancer in the early stages is a problem because of the lack of specific symptoms. Carcinoembryonic antigen, CA19‐9, CA‐50, and other tumor markers are currently used in the diagnosis of gastric cancer in clinical practice.[36](#cas13158-bib-0036){ref-type="ref"} These markers lack high sensitivity and specificity, particularly for early stage gastric cancer. Recently, multiple molecular biomarkers have been explored and reported to have potential efficacy as diagnostic and prognostic tools in gastric cancer. However, their use is still limited, and they need further validation to be used as markers of gastric cancer.[37](#cas13158-bib-0037){ref-type="ref"} The production of autoantibodies reflects greater immunologic reactivity in patients with cancer and enhanced immune surveillance for cancer cells.[38](#cas13158-bib-0038){ref-type="ref"} Autoantibodies to TAAs have recently received attention as potential biomarkers of cancer because they can be easily measured in serum obtained with minimally invasive blood sampling. Serum TAA levels are believed to increase even in very early stages of cancer.[39](#cas13158-bib-0039){ref-type="ref"}

We previously reported that several TAAs, including p53, tumor associated calcium signal transducer (TROP2), tripartite motif containing 21 (TRIM21), glucose transporter 1 (GLUT‐1), myomegalin, and New York esophageal squamous cell carcinoma 1 (NY‐ESO‐1), are useful to identify gastrointestinal malignant diseases.[6](#cas13158-bib-0006){ref-type="ref"}, [40](#cas13158-bib-0040){ref-type="ref"}, [41](#cas13158-bib-0041){ref-type="ref"} In the present study, we showed that the detection of autoantibodies to a panel of specific TAAs could have strong diagnostic power in patients with gastric cancer compared with the use of conventional tumor markers such as CEA and CA19‐9. Five TAAs that we chose in this study were reported to be potentially useful to detect cancer with high efficiency, even when only a single biomarker is used.[21](#cas13158-bib-0021){ref-type="ref"}, [22](#cas13158-bib-0022){ref-type="ref"}, [23](#cas13158-bib-0023){ref-type="ref"}, [27](#cas13158-bib-0027){ref-type="ref"}, [28](#cas13158-bib-0028){ref-type="ref"}, [31](#cas13158-bib-0031){ref-type="ref"} Consistent with these earlier data, our data on the individual sensitivities and specificities of all TAAs used in this study were enough to warrant further exploration. Serum p53 antibodies had the highest sensitivity among TAAs in our panel: 15.0% in the test cohort and 16.5% in the validation cohort. This sensitivity was almost equal to that of CEA alone (18.1%) and might surpass the sensitivity of CA19‐9 alone (14.1%) in this study. However, although all six of the antigens examined in our study have the potential to detect gastric cancer, similar to CEA and CA19‐9, none except p53‐Ab have come into widespread clinical usage.

On the basis of these results, it is apparent that a multiple‐autoantibody panel approach may improve the sensitivity associated with a single biomarker.[20](#cas13158-bib-0020){ref-type="ref"} In our cases, a six‐autoantibody panel had sensitivities of 49.0% and 52.0% in the test and validation cohorts, respectively. Moreover, autoantibodies statuses were not associated with traditional tumor markers, such as CEA and CA19‐9, statuses. A combination of a multiple‐autoantibody panel with these traditional tumor markers might have an additive effect on sensitivity. Furthermore, our multiple‐autoantibody panel can detect gastric cancer even as early as stage I. Surprisingly, the efficacy of the panel for detecting gastric cancer was not affected by any of the clinical features of the tumors that we assessed in this study: depth of tumor invasion (T1 or ≥T2), lymph node metastasis (+ or −), distant metastasis (+ or −), peritoneal dissemination (+ or −), or TNM stage (I or ≥II). Our data show that the levels of the traditional tumor markers CEA and CA19‐9 were elevated in advanced stages of cancer under most situations. This should mean that our panel of six TAAs helps distinguish patients with early‐stage gastric cancer from healthy controls.

It remains unclear whether autoantibody status affects the prognosis of cancer. Previous reports showed that increasing serum levels of p53‐Ab indicated a poor prognosis in patients with colorectal cancer.[42](#cas13158-bib-0042){ref-type="ref"}, [43](#cas13158-bib-0043){ref-type="ref"} On the contrary, Suppiah *et al*.[44](#cas13158-bib-0044){ref-type="ref"} reported that p53‐Ab was not related to the prognosis of colorectal cancer in long‐term follow‐up. In our present series, although the difference was not statistically significant, the autoantibody‐positive group had poorer survival than the autoantibody‐negative group. Although the prognostic impacts of other antigens have not been precisely evaluated, except for p53, expression of HSP70 was associated with reduced survival in patients with esophageal cancer.[45](#cas13158-bib-0045){ref-type="ref"} Serum HSP70 autoantibody reaction might reflect this biological effect. Moreover, upregulation of p90 is reported in a wide variety of malignant tumors.[46](#cas13158-bib-0046){ref-type="ref"}, [47](#cas13158-bib-0047){ref-type="ref"}, [48](#cas13158-bib-0048){ref-type="ref"}, [49](#cas13158-bib-0049){ref-type="ref"} Overexpression of p90 could be associated with worse prognosis and might serve as a prognostic marker in numerous human cancers. These findings might support our hypothesis that a positive ratio of TAAs was positively related to poor prognosis. Positive numbers of autoantibodies may correlate with poor prognosis in patients with gastric cancer in our study. Further examination and long‐term follow‐up will be needed to clarify this question.

In summary, this relatively large cohort study reports the clinical usefulness of a panel of six TAAs to diagnose gastric cancer, especially in its early stages. A peripheral blood test for autoantibodies is non‐invasive and has the advantages of lower cost and absence of side‐effects compared with invasive diagnostic methods.

Disclosure Statement {#cas13158-sec-0016}
====================

Hideaki Shimada received research grants and technical lecture fees from Medical & Biological Laboratories Co., Ltd., Nagoya, Japan. Akiko Kuwajima is an employee of Medical & Biological Laboratories Co., Ltd., Nagoya, Japan. The other authors have no conflict of interest.

AbbreviationsCAcarbohydrate antigenCEAcarcinoembryonic antigenHCChepatocellular carcinomaHSPheat shock proteinPrx VIperoxiredoxin VITAAtumor‐associated antigen

This work was partially supported by a grant for the Grant‐in‐Aid for Scientific Research (C) (Japan Society for the Promotion of Science \[Kakenhi\] nos. 15K10117 and 16K10520).
